Skip to content

ANI Pharmaceuticals ANIP Non-Cash Lease Expense

Non-Cash Lease Expense at other companies

AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$480K+4.3%

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Operating income$38.9M+48.5%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Cash & equivalents$311.2M+108%
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.88B+18.3%

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×
Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's non-cash lease expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's non-cash lease expense?
ANI Pharmaceuticals (ANIP) reported non-cash lease expense of $453K in Q1 2026.
How has ANI Pharmaceuticals's non-cash lease expense changed year-over-year?
ANI Pharmaceuticals's non-cash lease expense increased by 0.2% year-over-year, from $452K to $453K.
What does non-cash lease expense mean?
Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.